Particle Therapy Market to hit USD 1.7 Bn by 2032, says Global Market Insights Inc.
29 avr. 2024 04h30 HE
|
Global Market Insights Inc.
Selbyville, Delaware, April 29, 2024 (GLOBE NEWSWIRE) -- Particle Therapy Market Size will reach more than USD 1.7 billion by 2032. The surging global burden of cancer is an important trend...
Oncology Market Expected to Grow at 9.6% CAGR, Reaching USD 533.2 Bn by 2032 | DMR
24 avr. 2024 12h26 HE
|
Dimension Market Research
New York, April 24, 2024 (GLOBE NEWSWIRE) -- Overview According to Dimension Market Research, The Global Oncology Market size was valued USD 234.6 billion in 2023 and it is further anticipated...
Medicovestor Selected as Finalist to Present Its First-in-Class ADC Platforms at JP Morgan Asset Management: Life Sciences Innovation Summit
05 avr. 2024 10h00 HE
|
Medicovestor Inc
Medicovestor named finalist for JP Morgan Asset Management: Life Sciences Innovation Summit, showcasing pioneering ADC platforms on May 14th – 15th, 2024.
HNL Lab Medicine Unveils Lifesaving Cellular Therapy Laboratory
01 avr. 2024 14h01 HE
|
Health Network Laboratories (HNL Lab Medicine)
HNL Lab Medicine partners with LVHN to open cellular therapy laboratory, first in Lehigh Valley; capable of apheresis collections and stem cell processing
TeleDaaS™ Launches Y90 Treatment Planning Service and Announces Pilot Program for Early Adopters
25 mars 2024 08h02 HE
|
TeleDaas PLLC
TeleDaaS™ Launches Y90 Treatment Planning Service and Announces Pilot Program for Early Adopters
Ludwig Enterprises Inc (OTC:LUDG) Enters Booming Artificial Intelligence Cancer Screening Market with its Non-Invasive Cancer Diagnostics Testing Kit, launching within 2024
19 mars 2024 08h00 HE
|
Ludwig Enterprises, Inc.
SPARKS, Nev., March 19, 2024 (GLOBE NEWSWIRE) -- Ludwig Enterprises, Inc, (OTC: LUDG): A US-based biotechnology company is pleased to announce it has entered the booming artificial intelligence...
Ludwig Enterprises Inc. (OTC:LUDG) Announces Patent Filing for Breakthrough in Identifying mRNA Genes Associated with Certain Cancers
06 mars 2024 08h00 HE
|
Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc. (OTC: LUDG): A US-based biotechnology company is pleased to announce the successful filing of its provisional patent
Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
06 févr. 2024 08h30 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI)
05 févr. 2024 09h00 HE
|
ProLynx Inc.
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. announced today that the first patient was treated with PLX038 (PEGylated SN-38) in a Phase I/II clinical trial for primary CNS tumors...
Radiotherapy Market to grow by USD 12.2 billion by 2033, Globally at 5.9% CAGR | Market.us
29 janv. 2024 07h10 HE
|
Market.Us
New York, Jan. 29, 2024 (GLOBE NEWSWIRE) -- According to Market.us, the global radiotherapy market size is forecasted to exceed USD 12.2 billion by 2033, with a promising CAGR of 5.9% from 2024 to...